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IMPORTANCE Administration-to-birth intervals of antenatal corticosteroids (ANS) vary. The
significance of this variation is unclear. Specifically, to our knowledge, the shortest effective
administration-to-birth interval is unknown.
OBJECTIVE To explore the associations between ANS administration-to-birth interval and
survival andmorbidity among very preterm infants.
DESIGN, SETTING, AND PARTICIPANTS The Effective Perinatal Intensive Care in Europe (EPICE)
study, a population-based prospective cohort study, gathered data from 19 regions in 11
European countries in 2011 and 2012 on 4594 singleton infants with gestational ages
between 24 and 31 weeks, without severe anomalies and unexposed to repeated courses of
ANS. Data were analyzed November 2016.
EXPOSURE Time from first injection of ANS to delivery in hours and days.
MAIN OUTCOMES ANDMEASURES Three outcomeswere studied: in-hospital mortality; a
composite of mortality or severe neonatal morbidity, defined as an intraventricular
hemorrhage grade of 3 or greater, cystic periventricular leukomalacia, surgical necrotizing
enterocolitis, or stage 3 or greater retinopathy of prematurity; and severe neonatal brain
injury, defined as an intraventricular hemorrhage grade of 3 or greater or cystic periventricular
leukomalacia.
RESULTS Of the 4594 infants included in the cohort, 2496 infants (54.3%) were boys, and
themean (SD) gestational age was 28.5 (2.2) weeks andmean (SD) birth weight was 1213
(400) g. Mortality for the 662 infants (14.4%) unexposed to ANSwas 20.6% (136 of 661).
Administration of ANS was associated with an immediate and rapid decline in mortality,
reaching a plateau with more than 50% risk reduction after an administration-to-birth
interval of 18 to 36 hours. A similar pattern for timing was seen for the composite mortality or
morbidity outcome, whereas a significant risk reduction of severe neonatal brain injury was
associated with longer administration-to-birth intervals (greater than 48 hours). For all
outcomes, the risk reduction associated with ANSwas transient, with increasing mortality
and risk for severe neonatal brain injury associated with administration-to-birth intervals
exceeding 1 week. Under the assumption of a causal relationship between timing of ANS and
mortality, a simulation of ANS administered 3 hours before delivery to infants who did not
receive ANS showed that their estimated decline in mortality would be 26%.
CONCLUSIONS AND RELEVANCE Antenatal corticosteroidsmay be effective even if given only
hours before delivery. Therefore, the infants of pregnant women at risk of imminent preterm
delivery may benefit from its use.
JAMA Pediatr. 2017;171(7):1-9. doi:10.1001/jamapediatrics.2017.0602
Published online May 15, 2017.
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A ntenatal corticosteroids (ANS) reduce morbidity andmortality inpreterm infants andare recommended forwomenat riskofdeliverybefore34weeks’ gestation.1-5
Antenatal corticosteroids have been estimated to reduce in-
fant mortality by 31%, respiratory distress syndrome by 34%,
intraventricular hemorrhage by46%, andnecrotizing entero-
colitis by 54%.4
While there seems to be agreement that neonatal ben-
efits aremaximizedwhenANSare administered 24hours to 7
days before delivery,4,6-13 less is known about other and nar-
rower administration-to-birth intervals.5 In particular, to our
knowledge, the latest point at which ANS can be effectively
used is not known.3 Given favorable pharmacokinetics14 and
rapid circulatory effects,15-18 ANSmaybe effective evenhours
before birth. At the other end of the administration-to-birth
interval, some6-11 butnot all12,13 studies suggest decliningben-
efits from ANS if administered more than 7 days before pre-
term birth. Limitations in statistical power, varying
exposures,5,19 and outcomes6-13 may contribute to such di-
verse results and interpretations.
Because the problem of timely prediction of preterm de-
livery remains unresolved,20 administration of ANSwill con-
tinue to occur hours, days, or weeks before delivery. There-
fore, a more detailed understanding of the importance of the
administration-to-birth interval of ANS for infant outcome is
needed. The objective of this study was to investigate asso-
ciationsbetweendifferent administration-to-birth intervals of
ANS in hours andmorbidity andmortality in very preterm in-
fants.
Methods
The Effective Perinatal Intensive Care in Europe (EPICE) co-
hort study is apopulation-based studyon theuseof evidence-
basedpractices inverypretermbirthswith less than32weeks’
gestation in 19 regions across 11 European countries, con-
ducted in 2011 and 2012 (http://www.epiceproject.eu).21
Geographicandorganizationaldiversity, feasibility, andsample
size were accounted for when selecting regions. Inclusions
occurred over a 12-month period except in France (6-month
period). Ethics approval was obtained in each region, as
requiredbynational legislation. TheEuropean studywas also
approvedby theFrenchAdvisoryCommitteeonUseofHealth
Data inMedicalResearch (CCTIRS)andtheFrenchCommission
for Data Protection and Liberties (CNIL). Informed parental
consent (active or passive, depending on each participating
country’snational legislations)wasobtained; in some regions,
consent requirementswerewaivedbyethicsboards forparents
not included in the follow-upcohort (ie, stillbirthsandneonatal
deaths), as data were deidentified and from routine sources.
Study Population
From a total of 10 329 births, we excluded 2429 terminations
of pregnancy and stillbirths, 126 infants with severe congen-
ital anomalies, 2336 multiples, 300 infants born at 22 and 23
weeks’gestationalage (GA),22362 infantsofmotherswithmiss-
ing data on date and time of ANS administration, and 182 in-
fants ofmotherswhohad receivedmore than 1 course ofANS.
A repeated coursewasdefined as an interval betweenANS in-
jections exceeding 1week. The final sample consistedof 4594
singleton live-births at 24 to 31 weeks’ GA (Figure 1). Admin-
istration of corticosteroids during pregnancy for indications
other than preterm birth was not included in the study pro-
tocol.
Exposure
For each infant, informationwas collected ondates and times
of the first ANS injection as well as the total number of injec-
tions. Questionnaires were also sent to the heads of the ma-
ternity units regularlymanaging 10 ormore very preterm ad-
missions annually. Most maternity units (123 of 135 [91.1%])
responded, and protocols for ANS, including type of drug,
doses, and number and intervals of injections, were col-
lected.
We defined our exposure as time from the first injection
ofANS todelivery.We classifiedANSexposure in 4 categories
(no ANS, first injection <24 hours, first injection between 24
hours and 7 days, and first injection >7 days before birth) for
descriptive analyses of the characteristics ofwomenandnew-
borns and for comparison with other studies.6 For more de-
tailedanalysesof associationsbetween timingofANSandout-
come, we used administration-to-birth intervals as a
continuous variable. We did not include information on 1 or
Key Points
Question What is the shortest administration-to-birth interval of
antenatal corticosteroids that promotes survival and decreases
neonatal morbidity in very preterm infants?
Findings In a population-based cohort of 4594 European infants
born before 32 weeks’ gestation, we found that in-hospital
mortality was significantly reduced when antenatal corticosteroids
had been administered only a few hours prior to delivery.
Meaning Encouraging administration of antenatal corticosteroids
when delivery is very imminent could result in substantial survival
and health gains for very preterm infants.
Figure 1. Flowchart for Inclusions
10 329 Very preterm births 
(<32 weeks’ gestational age)
5735 Excluded
2429 Terminations of pregnancy
and stillbirths
2336 Multiples
362 With unknown timing of ANS
300 Births with <24 weeks of 
gestation
182 With repeated courses of ANS
126 With severe malformations
4594 Infants included
ANS indicates antenatal corticosteroids.
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several dosesofANSbecauseofhighcollinearitybetween tim-
ing of ANS and number of doses; 866 of 1111 women (77.9%)
receivingANS less than24hoursprior todelivery receivedonly
1 dose.
For somewomen,we only had information on the date of
ANS administration but not the time. This caused problems
for our classificationswhen administrationwaswithin 2 days
of delivery (204 of 1522 women [13.4%] delivering within 2
days). For a solution, we used multiple imputations chained
equations to impute these data based on all variables in the
study in addition to the time of delivery, date of administra-
tion, and number of injections received. We used 100 im-
puted data sets.23 Results are presented using imputed data.
Outcomes
Based on the evidence of the effects of ANS on preterm
infants,1-5 the outcomes selected were in-hospital mortality,
a composite ofmortality or severeneonatalmorbidity or both,
or severe neonatal brain injury. In-hospital mortality was de-
fined as death before discharge home. Severe neonatal mor-
biditywasdefined as an intraventricular hemorrhage gradeof
3 or 4,24 cystic periventricular leukomalacia,25 stage 3, 4, or 5
retinopathy of prematurity,26 or severe necrotizing enteroco-
litis (assessed as need for surgery or peritoneal drainage; Bell
stages27were not routinely recorded in all regions) among in-
fants discharged alive. Severe neonatal brain injury was de-
fined as an intraventricular hemorrhage grade of 3 or 4, cystic
periventricular leukomalacia,orboth.Wedidnot includebron-
chopulmonary dysplasia into our composite outcome be-
cause of regional variability in respiratory management and
oxygen saturation targets havemajor effects on rates of bron-
chopulmonary dysplasia.28
Covariables
Covariables that could be potential confounders of the asso-
ciations between timing of ANS and infant outcome were se-
lected based on the literature4,6,29-32 and clinical knowledge.
We included variables reflecting casemix (maternal age; par-
ity;pregnancycomplications, includingpreeclampsia, eclamp-
sia, and hemolysis, elevated liver enzyme levels, low platelet
count syndrome;pretermprelabor ruptureofmembranes;GA
[defined as best assessment basedon lastmenstrual periodor
antenatal ultrasonography, part of routine obstetric care in all
regions]; smallness for gestational age [definedasbirthweight
less than the third and between the third and 10th centiles,
based on customized intrauterine growth curves33]; and in-
fant sex) and variables related tomanagement of the delivery
(birth at a level III neonatal unit; mode of delivery; and deliv-
ery on same day as admission to hospital). Preeclampsia was
defined as hypertension after 20 weeks’ GA (blood pressure
of 140/90mmHgorhigher) andproteinuriawithaprotein level
of 0.3 g/L or greater, and eclampsia was defined as hyperten-
sion associated with convulsions or coma. Preterm prelabor
rupture ofmembraneswasdefinedas spontaneous rupture of
membranes 12 hours or more before onset of contractions.
Statistical Analyses
Wefirst comparedperinatal characteristics inour studypopu-
lation by timing of ANS administration using 4 categories.We
thenmodeled the associations between ANS administration-
to-birth intervalsandthe3outcomesusing the4-categoryvari-
able and a continuous variable in hours. For the latter analy-
sis,weused restricted cubic splineswith5knots locatedat the
fifth, 20th, 28th, 40th, and 95th percentiles (knots placed at
0, 1, 6, 24, and520hours) formortalityand thecompositemor-
talityandmorbidityoutcome.Weselected3knotsclose toeach
other because of strong nonlinearity in the first 24 hours af-
ter ANS. For severe neonatal brain injury,we used the default
percentiles (knots placed at 0, 6, 49, 122, and 525 hours) used
by Harrell.34 Generalized linear models, assuming a Poisson
distribution, were used to estimate risk ratios35 across expo-
sures for all analyses. Adjusted models included population
casemix and pregnancymanagement variables, as described
above. Region was included as a fixed effect, and we ac-
counted for clustering between observations within regions.
Finally, we assessed the effect on in-hospital mortality if
all infants without ANS had been administered ANS less than
3 hours, 3 to 5 hours, and 6 to 12 hours before delivery by re-
running our final 4-categorymodel and subdividing the less-
than-24-hours category into these subgroups; we then pre-
dicted mortality after setting the population with no ANS
sequentially to the first, second, and third subgroups.
M.N., A.P., and J.Z. analyzed the data. Analyses were car-
ried out using STATA version 14.0 SE (StataCorp).
Results
Themost commonANSprotocolwas two 12-mg injections 24
hours apart (performed in 105 of 123 units [85.4%]), followed
by two 12-mg injections 12 hours apart (performed in 13 units
[10.6%]). Another 4 units (3.3%) used other protocols. Beta-
methasone was used in 97 units (78.9%), dexamethasone in
6 units (4.9%), and both in 19 units (15.4%) (eTable 1 in the
Supplement).
Distribution of Administration-to-Birth Intervals
Fewer thanhalf of includedwomen (1871 of 4594 [40.7%]) re-
ceived ANS 24 hours to 7 days before delivery, ie, by current
standards, the administration-to-birth interval considered to
beoptimal.Manywomen receivedANScloser todelivery (1111
[24.2%]) or did not receive ANS (662 [14.4%]) (Table 1). The
cumulativedistributionofadministration-to-birth intervalsare
presented in eFigure 1 in the Supplement. Administration and
timing of ANS varied across the 19 European regions (eFigure
2 in the Supplement).
Perinatal Characteristics by Timing of ANS
Variables reflecting population case mix andmanagement of
pretermdeliverydifferedbetweenANScategories,with theex-
ception of infant sex (Table 1). In particular, women receiving
ANSmore than7daysbeforedeliveryweremore likely tohave
preterm prelabor rupture ofmembranes and a higher GA and
to deliver in a level III unit. Of patientswithmissing data, 235
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of 362 (64.9%) came from 3 of the 19 regions, reflecting diffi-
culties in data collection. After adjustment on region, infants
with missing information were more often born to mothers
with preeclampsia, more often delivered with cesarean sec-
tion, and less often born at level III units than infants in the
study population (eTable 2 in the Supplement).
Timing of ANS andOutcome
Using4 categories ofANS timing, anyANS—irrespective of the
administration-to-birth interval—wasassociatedwith lower in-
fantmortality thannoANS,with the largest risk reduction for
ANS administered 24 hours to 7 days before delivery (ad-
justed risk ratio, 0.5; 95% CI, 0.4-0.6). Antenatal corticoste-
roids administered24hours to 7days beforedeliverywas also
associatedwith lower risksofmortalityor severeneonatalmor-
bidity and of lower risk for severe neonatal brain injury than
no ANS (Table 2).
Increasing the resolutionof theanalysesbyexpressing the
risk for our 3outcomes as a continuous functionof the admin-
istration-to-birth interval, ANS less than 12hours before birth
was associated with an immediate and rapid decline in mor-
tality, followed by a slower risk reduction and reaching a pla-
teau with more than 50% risk reduction after an administra-
tion-to-birth interval of 18 to 36 hours (Figure 2). A similar
pattern for timing of ANS was seen for the composite out-
come of mortality or severe neonatal morbidity (eFigure 3 in
the Supplement), whereas a significant risk reduction of se-
vere neonatal brain injurywas associatedwith longer admin-
Table 1. Characteristics of Very Preterm Infants by 4 ANS Administration-to-Birth Intervals
Characteristic
ANS Administration-to-Birth Interval, No. (%)
P Value
No ANS
(n = 662
[14.4%])
<24 h
(n = 1111
[24.2%])
24 h-7 d
(n = 1871
[40.7%])
>7 d
(n = 950
[20.7%])
Infant
Gestational age, mean (SD), wk 28.3 (2.3) 28.5 (2.2) 28.4 (2.2) 28.8 (1.9) <.001
SGA, birth weight centiles
<.001
<3 104 (15.7) 204 (18.4) 487 (26) 224 (23.6)
3-10 62 (9.4) 103 (9.3) 221 (11.8) 79 (8.3)
>10 496 (74.9) 804 (72.4) 1162 (62.1) 647 (68.1)
Sex
.09Male 383 (57.9) 608 (54.8) 980 (52.4) 525 (55.3)
Female 279 (42.2) 503 (45.2) 890 (47.6) 425 (44.7)
Surfactant <2 h after birth
<.001No 282 (47.6) 560 (51.6) 1134 (61.9) 534 (58.4)
Yes 310 (52.4) 524 (48.4) 700 (38.2) 381 (41.6)
Maternal
Age, mean (SD), y 28.9 (6.4) 29.6 (6.2) 30.4 (6.1) 30.5 (6.2) <.001
Parity
<.001Primiparous 330 (50.7) 625 (56.7) 1073 (57.7) 441 (46.9)
Multiparous 321 (49.3) 477 (43.3) 787 (42.3) 500 (53.1)
Preeclampsia/eclampsia/HELLP
<.001No 565 (89.4) 888 (80.9) 1381 (74) 808 (85.9)
Yes 67 (10.6) 209 (19.1) 484 (26) 133 (14.1)
PPROM
<.001No 580 (91.5) 972 (88.4) 1265 (67.8) 540 (57.4)
Yes 54 (8.5) 127 (11.6) 600 (32.2) 401 (42.6)
Mode of delivery onset
<.001Spontaneous or induced 414 (63.6) 662 (60.1) 918 (49.5) 507 (53.9)
Cesarean section 237 (36.4) 439 (39.9) 936 (50.5) 433 (46.1)
Mode of delivery
<.001Vaginal 312 (48.1) 450 (40.9) 596 (32.1) 276 (29.3)
Cesarean section 337 (51.9) 652 (59.2) 1263 (67.9) 667 (70.7)
Delivery at level III unita
<.001No 283 (42.9) 379 (34.1) 311 (16.6) 133 (14)
Yes 376 (57.1) 731 (65.9) 1559 (83.4) 817 (86)
Delivery on day of admission
<.001No 203 (32.6) 605 (56.3) 1725 (94.9) 802 (88.2)
Yes 419 (67.4) 469 (43.7) 94 (5.2) 107 (11.8)
Abbreviations: ANS, antenatal
corticosteroids; HELLP, hemolysis,
elevated liver enzyme levels, low
platelet count syndrome; PPROM,
preterm prelabor rupture of
membranes; SGA, smallness for
gestational age.
a Level III neonatal units were defined
using local definitions of level of
care.
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istration-to-birth intervals (Figure3). For all outcomes, the risk
reduction associatedwithANSwas transient,with increasing
mortality and risk for severe neonatal brain injury associated
with ANS administration-to-birth intervals of 5 to 7 days or
more.
Figure 2. Association Between Timing of Antenatal Corticosteroids
(ANS) and In-Hospital Mortality in 4594 Very Preterm Infants
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The reference relative risk represents very preterm infants who were not
exposed to ANS before birth. The curves for adjusted relative risks represent
means and 95% CI bands.
Figure 3. Association Between Timing of Antenatal Corticosteroids
(ANS) and Severe Neonatal Brain Injury in 4594 Very Preterm Infants
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The reference relative risk represents very preterm infants who were not
exposed to ANS before birth. The curves for adjusted relative risks represent
means and 95% CI bands. cPVL indicates cystic periventricular leukomalacia;
IVH, intraventricular hemorrhage.
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In a simulation of providingANS for the 661 infants in the
sample who did not receive ANS, our model predicted a 26%
decrease in mortality if these infants received ANS at least 3
hours before delivery, a 37% decrease if they received ANS 3
to 5hours before delivery, and a 51%decrease if they received
ANS 6 to 12 hours before delivery (eTable 3 in the Supple-
ment).
Discussion
Our findings suggest that infantmortalitywas rapidly and sig-
nificantly reduced when ANS were administered only a few
hours before delivery. Infant birth 12 hours followingANS ad-
ministrationwasassociatedwithsimilarmortality riskas those
exposed to ANS 18 to 48 hours before delivery. Under the as-
sumption of a causal relationship between timing of ANS and
mortality, our simulations showed that if infantswith noANS
prior to delivery received ANS 6 to 12 hours before delivery,
their mortality was estimated to have been reduced by 51%.
Furthermore, the administration of ANSwas associated with
a significant reduction in severe neonatal morbidity.
Our findings challenge current thinking about the opti-
mal timing ofANS. Previously, ANS administered less than24
hours before birth have been referred to as suboptimal,36
partial,12 or incomplete,9 suggestingpoorereffectivenessatad-
ministration-to-birth intervals less than 24 hours. However,
the categories used in previous studies appear to have hid-
den clinically important effects of ANS occurring within this
period. In addition, given thatmost (77.9%) pregnantwomen
in our study delivering within 24 hours of ANS only received
1 injection, significant effectsmaybeachievedbya singleANS
injection.19 In this context, we note with interest the recent
statement by theNational Institute forHealth andCareExcel-
lence Guideline Development Committee3; taking account of
the pharmacological mechanism of action of ANS, the com-
mittee suspects that any benefits from ANS would likely be
transferredeven if therewasonly a limitedamountof timebe-
tween administration and time of birth.
The underlying mechanisms for the rapid actions of ANS
suggested herein are not fully understood. Cord blood con-
centrations of ANS peak 1 hour after administration to the
mother and becomeundetectable 2 days after the last dose.14
While induction of many corticosteroid effects involve ge-
nomic interactions and therefore take time,18 nongenomic ef-
fectsof corticosteroidshave inmore recentyears alsobeendis-
covered. These effects can be very rapid and occur within
minutes.17,18 Nongenomic effects may contribute to findings
in preterm lambs, demonstrating beneficial corticosteroid ef-
fects onpulmonary edemaandbloodpressurewithin 8hours
after administration and significant lung function improve-
mentwithin 15hours.16 Inhumans, fetalmovementsandheart
variability increasedsignificantlywithin8hoursafterANS,pos-
sibly indicating fetal well-being or fetal stress enhancing
maturation.15
Although the risk reduction was slower than that associ-
atedwith survival—suggesting competing outcomes (mortal-
ity andmorbidity) or that theunderlyingmechanismsmaybe
different—anANSadministration-to-birth interval of 48hours
to 1 week was associated with a significantly reduced risk for
severe neonatal brain injury. A lower risk of severe neonatal
brain injury after ANS has previously been reported for pa-
tients at highest risk, ie, those born extremely preterm.22 A
lower risk after a partial course of ANS has also been
demonstrated.37 In these patients, theANS-associated reduc-
tion insevereneonatalbrain injurymediatedprotectionagainst
later neurodevelopmental impairment.22,37
Weobserved a40% increasedmortality in infantswith an
ANSadministration-to-birth interval greater than7days com-
paredwithan intervalof 1 to7days, agrouprepresenting 18.8%
ofall infants inourstudy. In2015,Melamedetal6 reportedsimi-
lar findings using the Canadian Neonatal Network. Repeated
courses of corticosteroids (betamethasonewas the only drug
tested) have been associated with a reduction in the inci-
dence of respiratory distress syndrome and possibly also se-
verity of neonatal lung disease.38 At 2-year to 3-year follow-
up, therewasnoevidenceof either significant benefit or harm
with a repeated course of ANS in terms of rates of neurosen-
sory disabilities, developmental delay, or growth failure.2,3,38
Follow-up inmidchildhooddemonstrated long-termsafety.39
Strengths and Limitations
Thestrengthsofour study include itsprospectivedesign, large
size, andheterogeneouspopulation includingboth tertiaryand
nontertiary centers all over Europe. This ensures generaliz-
ability toawide rangeof settings.Casemix,mortality, andmor-
bidity rates are within the same ranges as previously re-
ported fromotherhigh-incomecountries.6Wehadpower and
data in sufficient detail to perform adjusted analyses on tim-
ing of ANS andoutcome at very short administration-to-birth
intervals. The outcomes—infant survival andmajor neonatal
morbidities—were robust and clinically highly relevant.
Our study also has limitations. Even thoughwe excluded
infantswithmalformations and infants bornbefore 24weeks’
GA, and even after adjusting for group differences presented
in Table 1, residual confounding may have occurred, as the
populations of women who delivered at various points after
ANS administration may have been different. We investi-
gated several outcomes, andmultiple confidence intervals are
reported in this article; caution shouldbeappliedwhenevalu-
ating their joint statistical level. The EPICE database does not
contain informationon timeof admission, sowecouldnotde-
termine admission-to-administration intervals. In addition,
reasons for not treating pregnant women with ANS were not
available, andwe cannot exclude thatwithholding treatment
may have occurred in some cases, especially at the lower end
of GAs. However, we were able to adjust for a wide range of
perinatal characteristics as well as factors reflectingmanage-
ment.
Inourcohort, 7.0%ofwomenreceivedANSbuthadnodata
on timing of administration; comparison of their characteris-
tics suggests that thesemissing datamay represent emergen-
cies with suboptimal documentation. Some women had in-
complete data on timing; for these patients,weusedmultiple
imputation, which yielded results similar to complete case
analysis. Our study was descriptive with no attempts in the
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study framework to standardize treatment, and therefore,we
wereunable to investigatewhether one corticosteroid (or one
particular dosing regimen) has advantages over another.5,19
Conclusions
In conclusion, our results suggest significant health-
promoting effects of ANS beginning just hours before deliv-
ery. This new knowledge encourages a more proactive man-
agement of women at risk for imminent preterm birth, which
mayhelp reduce infantmortality andsevereneonatal brain in-
jury.Ourstudyalsohighlights thata largeproportionofwomen
remainat risk forverypretermbirthmore than7daysafterANS
and that their infants have increased morbidity and mortal-
ity.We suggest that future research areas should include test-
ing optimal dosing (1 vs 2 doses) and dosing intervals of ANS.
Given the suggestion of very rapid action, immediate postna-
tal corticosteroid rescue for very preterm infants unexposed
to ANS could also be a topic for future research.
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